Characteristics and transplant outcome of myeloid sarcoma: a single-institute study

We performed a retrospective study describing the characteristics of myeloid sarcoma (MS) and evaluated the outcome of hematopoietic stem cell transplantation (HSCT) in patients with MS. There were 27 patients with de novo isolated MS, 34 with de novo leukemic MS and 13 with secondary leukemic MS in our study. Sixty-three patients received induction chemotherapy. Following induction therapy, 35 patients underwent HSCT, including 10 autogenous HSCT (auto-HSCT) and 25 allogeneic HSCT (allo-HSCT) cases. Compared with intensive chemotherapy only as consolidation treatment, HSCT (auto-/allo-HSCT) significantly improved the overall survival (OS) of MS patients ( p < 0.05), while allo-HSCT also improved progression-free survival (PFS, p = 0.032). According to multivariate analysis, poorer prognosis in terms of OS was observed in older patients ( p = 0.024, HR = 1.030, 95% CI 1.004–1.057), while HSCT (auto/allo-HSCT) had a favorable impact on OS for patients with MS (auto-HSCT, p = 0.044, HR = 0.201, 95% CI 0.042–0.959; allo-HSCT, p = 0.038, HR = 0.341, 95% CI 0.124–0.943). Extramedullary disease without complete remission (CR) after induction therapy was the sole variable independent of high OS and PFS ( p = 0.049, HR = 2.243, 95% CI: 1.005–5.005; p = 0.017, HR = 2.535, 95% CI 1.180–5.448, respectively). The data indicate that HSCT is an effective treatment for patients with MS who have achieved CR of extramedullary disease after induction therapy.